▮ More

Rigel Pharmaceuticals Inc. Q4 Earnings Summary

By RTTNews Staff Writer ✉ | Published: 3/5/2024 4:04 PM ET |

Below are the earnings highlights for Rigel Pharmaceuticals Inc. (RIGL):

Earnings: $0.74 million in Q4 vs. $1.40 million in the same period last year.
EPS: $0.00 in Q4 vs. $0.01 in the same period last year.
Analysts projected -$0.03 per share
Revenue: $35.79 million in Q4 vs. $51.28 million in the same period last year.

For comments and feedback contact: editorial@rttnews.com

Biotech Stocks Facing FDA Decision In April 2024

Biotech Stocks Facing FDA Decision in March 2024

Biotech Stocks Facing FDA Decision In November 2023

AbbVie To Collaborate With Gilgamesh To Develop Next-Gen Psychiatric Therapies

Mt. Capra Recalls Goat Milk Formula Recipe Kit, Urges Not To Use As Infant Formula

Amazon, Microsoft, Pfizer To Invest Billions In French Projects

Western Mixers Recalls Yogurt Covered Pretzels

Novartis' Scemblix Gets Breakthrough Designation For Chronic CML

CPSC Recalls: UTVs, Snowmobiles, Wall Ovens, Chairs, Toy Pinwheels, Nightgowns

Texas Pecan Recalls Select Nuts, Snack Mixes, Seeds, Snack Sticks

Novavax Stock More Than Doubles On Deal With Sanofi To Co-commercialize Covid-19 Vaccine

SoftBank Posts Narrower Loss In FY23; Net Sales Up 2.8%

Rheinmetall AG Bottom Line Declines In Q1

Bayer Q1 Profit Down; Confirms FY Currency-adj. Forecast

Rigel Pharmaceuticals Inc. Q4 Earnings Summary

AbbVie To Collaborate With Gilgamesh To Develop Next-Gen Psychiatric Therapies

Mt. Capra Recalls Goat Milk Formula Recipe Kit, Urges Not To Use As Infant Formula

Amazon, Microsoft, Pfizer To Invest Billions In French Projects

Western Mixers Recalls Yogurt Covered Pretzels

Novartis' Scemblix Gets Breakthrough Designation For Chronic CML

CPSC Recalls: UTVs, Snowmobiles, Wall Ovens, Chairs, Toy Pinwheels, Nightgowns

Texas Pecan Recalls Select Nuts, Snack Mixes, Seeds, Snack Sticks

Novavax Stock More Than Doubles On Deal With Sanofi To Co-commercialize Covid-19 Vaccine

SoftBank Posts Narrower Loss In FY23; Net Sales Up 2.8%

Rheinmetall AG Bottom Line Declines In Q1

Bayer Q1 Profit Down; Confirms FY Currency-adj. Forecast

Nu Holdings Ltd. Announces Rise In Q1 Income, But Misses Estimates

Novartis' Scemblix Gets Breakthrough Designation For Chronic CML

Novavax Q1 Loss Narrows, Beats Estimates; Revises Down Annual Revenue Guidance Below View - Update

Aethlon Medical Stock Surges In Pre-market On Positive Hemopurifier Trial Results

Merck Discontinues Vibostolimab And Pembrolizumab Coformulation Arm Of Phase 3 Trial In Melanoma

Polar Semiconductor To Receive About $195 Mln For Expansion Of Minnesota Facility

Alibaba Down 4% In Pre-Market On Earnings Miss

Moderna: FDA Delays BLA Review Of RSV Vaccine MRNA-1345

Western Mixers Recalls Yogurt Covered Pretzels

ZEEKR Intelligent Announces IPO Of 21 Mln ADSs At $21/ADS

First American Financial's Subsidiary Buys Wisconsin Title Service's Subsidiary, Plants

Fulcrum Therapeutics Stock Climbs In Pre-market On License Deal With Sanofi For Losmapimod

Anglo American Accelerates Portfolio Simplification

Lifeway Foods Inc Reveals Advance In Q1 Profit, But Misses Estimates

Pixelworks Inc. Q1 Loss Drops, Inline With Estimates

Singulus Q1 Revenue Improves; Expects Annual Sales To Rise

Cancom Group Q1 Revenue Improves; Backs Annual Guidance

Hunting Bags $145 Mln OCTG Order From Kuwait Oil Company

Biocryst Pharma's Orladeyo Approved In Mexico For Hereditary Angioedema Attacks

Syra Health To Serve As Subcontractor For Luke For Defense Health Agency